BOS-589
As of the edition of 20 October 2026, BOS-589 is a drug: went quiet in 2020; acts on RET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Unknown
- Registered trials
- 2, 0 stopped early
- Disease areas
- Digestive system; Cancer; Hormones; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of BOS-589.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | P07949 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2017 to now |
| Boston Pharmaceuticals | Lead sponsor of trials | 2019 to now |